New York Deal With Gilead Lowers Cost of State-Purchased HIV Drugs
March 20, 2014
This article was reported by Times Union.
The Times Union reported that New York State is one step closer to its goal of reducing HIV infection among residents, thanks to an agreement between the state and a major pharmaceutical company to provide antiretroviral (ARV) drugs at lower cost. State Health Commissioner Nirav R. Shah announced the arrangement with Gilead Sciences, Inc., on March 19. Gilead is thought to control 40 percent of the ARV market share. HIV activists hope other drug makers will follow Gilead's lead.
With more than 60,000 of New York's HIV-positive residents getting their medications through Medicaid, the state purchases a large volume of ARV drugs. According to Shah, it costs $379,000 to treat an HIV patient through their lifetime. ARV drugs control the transmission of HIV; more affordable access will mean a big overall cost savings.View Full Article
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)